India’s largest SME IPO ever, Q-Line Biotech, has secured INR 61.09 crore from a roster of marquee institutional investors ahead of its record-breaking INR 214.48-crore IPO.
Q-Line Biotech anchor book allocation was finalised on 20 May 2026. It is drawing intense market attention due to the participation of some of Dalal Street’s most prominent names. The entry of veteran investors into the issue signals a major vote of confidence for retail investors.
Q-Line Biotech Anchor Round: Details
Q-Line allotted 17.81 lakh equity shares at the upper price band of INR 343 per share to 18 institutional investors. The distribution of the anchor book highlights significant backing from top-tier funds:
- The Abakkus Entry: Sunil Singhania’s Abakkus Mutual Fund picked up 2.91 lakh shares (16.37% of the anchor portion) through the Abakkus Small Cap Fund. Abakkus is the largest investor in the Q-Line Biotech IPO.
- Carnelian AIF: Led by Vikas Khemani, the fund secured the second-largest allocation of 2.71 lakh shares (15.25%).
- Sanshi Fund-I: Associated with renowned investor Mukul Agrawal, the fund was allotted 1.43 lakh shares (8.04%).
- Other Key Participants: The book also saw strong demand from Bharat Venture Opportunities Fund (Sunil Singhania), India Max Investment Fund, Tiger Strategies Fund, and HDFC Bank Limited.
For retail and high-net-worth individual (HNI) investors, an anchor book of this pedigree acts as a powerful barometer of trust.
As seasoned fund managers like Sunil Singhania, Vikas Khemani, and Mukul Agrawal commit capital to an SME company, it provides a strong validation of Q-Line Biotech’s business model, valuation, and corporate governance. Their participation effectively de-risks the issue perception, signalling institutional confidence in the company’s long-term scalability.
Full List of Anchor Investors in Q-Line Biotech IPO
| Name of Anchor Investor | Equity Shares Allocated | % of Anchor Portion | Total Amount (INR Cr) |
| Abakkus Small Cap Fund | 2,91,600 | 16.37% | 10.00 |
| Carnelian AIF Category I Trust | 2,81,600 | 15.81% | 9.66 |
| India Max Investment Fund | 2,27,600 | 12.78% | 7.81 |
| Bharat Venture Opportunities Fund | 2,00,000 | 11.23% | 6.86 |
| Meru Investment Cell | 1,43,200 | 8.04% | 4.91 |
| Sanshi Fund-I | 1,43,200 | 8.04% | 4.91 |
| Institutional Fund / Trust | 87,600 | 4.92% | 3.00 |
| Tiger Strategies Fund | 58,400 | 3.28% | 2.00 |
| Finavenue Capital Trust | 57,200 | 3.21% | 1.96 |
| Hem Growth Opportunities Fund | 57,200 | 3.21% | 1.96 |
| 360 ONE LVF Treasury | 29,200 | 1.64% | 1.00 |
| HDFC Bank Limited | 29,200 | 1.64% | 1.00 |
| Innovative Vision Fund | 29,200 | 1.64% | 1.00 |
| Navbharat Investment Trust | 29,200 | 1.64% | 1.00 |
| Rajasthan Global Securities Pvt. Ltd. | 29,200 | 1.64% | 1.00 |
| Religo Commodities Ventures Trust | 29,200 | 1.64% | 1.00 |
| Sunrise Investment Opportunities Fund | 29,200 | 1.64% | 1.00 |
| Tattvam AIF Trust | 29,200 | 1.64% | 1.00 |
| Total | 17,81,200 | 100% | 61.10 |
Q-Line Biotech IPO Mechanics and Financial Positioning
The institutional interest in Q-Line’s anchor allocation is backed by a robust operational track record. As an integrated in-vitro diagnostics (IVD) company, Q-Line has capitalised on the government’s “Make in India” initiative, operating four manufacturing facilities across Lucknow and Delhi.
Key Financial Metrics:
- Revenue Growth: Climbed from INR 203.65 crore in FY24 to INR 313.78 crore in FY25. For the 9M FY26, revenue stood at INR 232.42 crore.
- Profitability: The company reported a Profit After Tax (PAT) of INR 28.13 crore in FY25, accelerating to INR 38.69 crore in just the first nine months of FY26.
Issue Details: The INR 214.48-crore public issue is entirely a fresh issue of 62.53 lakh equity shares.
- Price Band: INR 326–343 per share
- Subscription Window: 21 to 25 May 2026
- Objective: Proceeds will fund working capital requirements and the repayment of borrowings.
With its subscription window now open, Q-Line Biotech’s IPO is poised to test market depth, armed with an anchor book that has already redefined institutional participation in the SME space.
Rajat Bhati has a strong technical background and 5 years of experience in the stock market. He focuses on equity research, technical analysis, IPO valuations, and risk management, helping investors make clearer, data-backed decisions. Today, he works full-time to educate people about the opportunities in IPO market.
